448 related articles for article (PubMed ID: 19369230)
21. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status.
Servais S; Dumontier N; Biard L; Schnepf N; Resche-Rigon M; Peffault de Latour R; Scieux C; Robin M; Meunier M; Xhaard A; Sicre de Fontbrune F; Le Goff J; Socié G; Simon F; Mazeron MC
Clin Microbiol Infect; 2016 Mar; 22(3):289.e1-7. PubMed ID: 26627339
[TBL] [Abstract][Full Text] [Related]
22. CMV-infected kidney grafts drive the expansion of blood-borne CMV-specific T cells restricted by shared class I HLA molecules via presentation on donor cells.
Gatault P; Al-Hajj S; Noble J; Chevallier E; Piollet M; Forconi C; Gaudy-Graffin C; Thibault G; Miquelestorena-Standley E; Halimi JM; Büchler M; Lemoine R; Baron C
Am J Transplant; 2018 Aug; 18(8):1904-1913. PubMed ID: 29377506
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection.
Gergely KM; Podlech J; Becker S; Freitag K; Krauter S; Büscher N; Holtappels R; Plachter B; Reddehase MJ; Lemmermann NAW
Front Immunol; 2021; 12():694588. PubMed ID: 34489940
[TBL] [Abstract][Full Text] [Related]
24. Insufficient Antigen Presentation Due to Viral Immune Evasion Explains Lethal Cytomegalovirus Organ Disease After Allogeneic Hematopoietic Cell Transplantation.
Holtappels R; Schader SI; Oettel O; Podlech J; Seckert CK; Reddehase MJ; Lemmermann NAW
Front Cell Infect Microbiol; 2020; 10():157. PubMed ID: 32351904
[TBL] [Abstract][Full Text] [Related]
25. Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation.
Espigado I; de la Cruz-Vicente F; BenMarzouk-Hidalgo OJ; Gracia-Ahufinger I; Garcia-Lozano JR; Aguilar-Guisado M; Cisneros JM; Urbano-Ispizua A; Perez-Romero P
Transpl Int; 2014 Dec; 27(12):1253-62. PubMed ID: 25070273
[TBL] [Abstract][Full Text] [Related]
26. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
[TBL] [Abstract][Full Text] [Related]
27. Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients.
Ciáurriz M; Beloki L; Zabalza A; Bandrés E; Mansilla C; Pérez-Valderrama E; Lachén M; Rodríguez-Calvillo M; Ramírez N; Olavarría E
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921749
[TBL] [Abstract][Full Text] [Related]
28. Recovery of CMV-specific CD8+ T cells and Tregs after allogeneic peripheral blood stem cell transplantation.
Pastore D; Delia M; Mestice A; Perrone T; Carluccio P; Gaudio F; Giordano A; Rossi AR; Ricco A; Leo M; Liso V; Specchia G
Biol Blood Marrow Transplant; 2011 Apr; 17(4):550-7. PubMed ID: 20457268
[TBL] [Abstract][Full Text] [Related]
29. Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis.
Limaye AP; Green ML; Edmison BC; Stevens-Ayers T; Chatterton-Kirchmeier S; Geballe AP; Singh N; Boeckh M
J Infect Dis; 2019 Jul; 220(5):752-760. PubMed ID: 31112280
[TBL] [Abstract][Full Text] [Related]
30. Expansion of effector memory Vδ2
Huang Y; Jiang C; Zhu J; Lin L; Mao M; Yin T; Cai G
Front Immunol; 2024; 15():1397483. PubMed ID: 38915409
[TBL] [Abstract][Full Text] [Related]
31. Functional profile of cytomegalovirus (CMV)-specific CD8+ T cells and kinetics of NKG2C+ NK cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients.
Muñoz-Cobo B; Solano C; Benet I; Costa E; Remigia MJ; de la Cámara R; Nieto J; López J; Amat P; Garcia-Noblejas A; Bravo D; Clari MÁ; Navarro D
J Med Virol; 2012 Feb; 84(2):259-67. PubMed ID: 22170546
[TBL] [Abstract][Full Text] [Related]
32. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
33. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
Fleming T; Dunne J; Crowley B
J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
[TBL] [Abstract][Full Text] [Related]
34. Anti-CMV-IgG positivity of donors is beneficial for alloHSCT recipients with respect to the better short-term immunological recovery and high level of CD4+CD25high lymphocytes.
Jaskula E; Dlubek D; Tarnowska A; Lange J; Mordak-Domagala M; Suchnicki K; Sedzimirska M; Borowik A; Mizia S; Lange A
Viruses; 2015 Mar; 7(3):1391-408. PubMed ID: 25807050
[TBL] [Abstract][Full Text] [Related]
35. Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients.
Pipeling MR; John ER; Orens JB; Lechtzin N; McDyer JF
J Infect Dis; 2011 Dec; 204(11):1663-71. PubMed ID: 22021622
[TBL] [Abstract][Full Text] [Related]
36. Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.
La Rosa C; Longmate J; Lingaraju CR; Zhou Q; Kaltcheva T; Hardwick N; Aldoss I; Nakamura R; Diamond DJ
Biol Blood Marrow Transplant; 2019 Apr; 25(4):771-784. PubMed ID: 30562587
[TBL] [Abstract][Full Text] [Related]
37. Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT.
Tormo N; Solano C; Benet I; Nieto J; de la Cámara R; López J; Garcia-Noblejas A; Muñoz-Cobo B; Costa E; Clari MA; Hernández-Boluda JC; Remigia MJ; Navarro D
Bone Marrow Transplant; 2011 Nov; 46(11):1437-43. PubMed ID: 21243030
[TBL] [Abstract][Full Text] [Related]
38. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
[TBL] [Abstract][Full Text] [Related]
39. Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.
Shabir S; Kaul B; Pachnio A; Banham GD; Smith H; Chand S; Jham S; Harper L; Ball S; Rahbar A; Söderberg-Nauclér C; Moss P; Borrows R
J Am Soc Nephrol; 2013 Oct; 24(10):1698-708. PubMed ID: 23847277
[TBL] [Abstract][Full Text] [Related]
40. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients.
Ugarte-Torres A; Hoegh-Petersen M; Liu Y; Zhou F; Williamson TS; Quinlan D; Sy S; Roa L; Khan F; Fonseca K; Russell JA; Storek J
Biol Blood Marrow Transplant; 2011 Apr; 17(4):574-85. PubMed ID: 20688181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
